GlassScriptPhysician profile
Matthew Lazette
NPI 1225521511
$5,164.30
in general payments reported to CMS, 2019-2025
30 companies · $87.19 in 2025
The $87.19 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,313 · 2022: $1,977 · 2023: $1,693 · 2024: $94.27 · 2025: $87.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $716.64 | 2021-2023 | |
| Novo Nordisk INC | $671.87 | 2021-2023 | Wegovy, Saxenda, Rybelsus |
| Lilly USA, LLC | $455.87 | 2021-2025 | Emgality, Jardiance, Mounjaro |
| Corcept Therapeutics | $451.78 | 2021-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $288.13 | 2021-2023 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $262.42 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.13 | 2021-2023 | Jardiance, Stiolto Respimat |
| Exact Sciences Corporation | $229.44 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $224.35 | 2022 | |
| Pfizer INC. | $166.97 | 2021-2023 | |
| Amgen INC. | $165.31 | 2021-2023 | Repatha, Otezla, Prolia |
| Genentech USA, INC. | $132.37 | 2021-2022 | |
| Axsome Therapeutics, INC. | $126.48 | 2022-2023 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $125.36 | 2021-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $113.01 | 2021-2025 | Dificid, Gardasil 9, Capvaxive |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $102.14 | 2021-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $99.59 | 2022-2023 | Trintellix |
| Jazz Pharmaceuticals INC. | $83.19 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.90 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.22 | 2021-2023 | |
| Amarin Pharma, INC. | $59.60 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $58.72 | 2022-2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $57.80 | 2021 | |
| Sumitomo Pharma America, INC. | $50.00 | 2023 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $37.38 | 2021 | |
| Phadia US INC. | $33.47 | 2023-2024 | Immunocap |
| Upsher-Smith Laboratories LLC | $21.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.71 | 2021 | |
| Kaleo, INC. | $13.04 | 2021 | |
| Endogastric Solutions, INC | $9.64 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lazette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.